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The term ‘‘big data’’ has often been used as an all-
encompassing phrase for research that involves the use of
large-scale data sets. However, the use of the term does little
to signify the underlying complexity of definitions, of data
sets, and of the requirements that need to be taken into
consideration for sustainable research and the estimation of
downstream impact. In particular, ‘‘big data’’ is frequently
connected with biobanks and biobank networks as the in-
stitutions involved in tissue preservation are increasingly
and perhaps unavoidably linked to the de facto preservation
of information.
‘‘Big data’’ is commonly defined as collections of data
sets so large and complex that its manipulation and man-
agement present significant logistical challenges (Oxford
English Dictionary, 2013). Within the sphere of clinically
oriented research, the term is often synonymous to elec-
tronic patient records from large hospitals, clinical trials,
and/or -omics-based consortia and their associated banked
samples. These data can be structured or unstructured, gen-
erated from diverse sources (sometimes in real time), and in
very large volumes.
‘‘Big Data’’ and Biobanking
Despite the much anticipated revolution in healthcare, the
path from big data to clinical impact for specific research
questions remains unclear. Clinically oriented biobanks are
important sources for the provision of research-ready tissue
as well as associated data under best practices, as an added-
value proposition to their users. However, they do face a
dual harmonization bottleneck of analytical laboratory and
of digital techniques (data collection, curation, and stor-
age). Both of these aspects can affect directly the biobank
utilization rates and long-term sustainability.
The data contained within biobanks can be generated
upon sample collection and/or through the retrospective
linkage to medical/research records within their respec-
tive healthcare/academic institutions, resulting in a transfer
and storage of the additional information. This connection is
usually achieved through the deterministic linkage of sam-
ples and data from within clinical records using a unique
identifier, such as hospital number, and a ‘‘key’’ that con-
nects it to a banked sample in a secure manner. In a similar
process, -omics data, for example, can be added to the ac-
companying sample information. However, the lack of reli-
able metrics to characterize the outcome of this data accrual
can potentially confound the impact of such efforts.
Time for ‘‘Big Data Metrics’’
The continuous collection of information for banked
samples from different sources can create a heteroge-
neous information repository, especially as different sub-
sets from a biobank’s collections are used for different
purposes—producing and sometimes returning different
data. Indeed such a situation can occur at a high rate and
the most practical approach might be that of characteriz-
ing the data according to biobank ‘‘big data metrics.’’ The
European Nucleotide Archive (ENA) provides a useful
example, where the experience of the last 30 years has
resulted in three tiers of data, divided simply into unpro-
cessed, processed, and interpreted information. The exis-
tence of data norms and recording of parameters relate to
each one of these tiers.
In biobanking, three central questions can form the core of
such metrics: (i) the type of information (raw/processed), (ii)
the depth of detail (number of set parameters, structured/un-
structured), and (iii) the completion status of the data (using
perhaps the definitions of Accuracy, Timeliness, Compar-
ability, Usability, and Relevance as adopted by the Canadian
Institute for Health Information, 2009, and the European Sta-
tistical System, 2003). These three parameters are universally
understood, provide a comparative measure, and could be
potentially implemented as metrics or at least investigated by
biobanks as part of the extant diverse range of Laboratory
Information Management Systems.
The adoption of such descriptive ‘‘big data’’ metrics in bio-
banking could ease the difficulties of managing the expanding
sets of deposited information alongside physically banked
samples. In addition as biobanking networks continue to de-
velop shared platform infrastructures (e.g., the EuPA Biobank
Initiative), the characterization of the information already con-
tained within their individual collections becomes an imperative
prerequisite to a potential combination and subsequent recon-
ciliation of data from different sources.
It Is the Tool, Not the Solution
‘‘Big data metrics’’—when developed—will become a tool
for the management of biobanking growth, not necessarily a
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solution. The speed with which biobanks have to deal with and
assimilate technological change is considerable and fre-
quently with significant associated costs. The addition of
another tool, however useful, might also conceal additional
costs and might need supporting evidence before any wide
adoption considerations. These costs could be addressed by
major research initiatives, such as the recent Big Data to
Knowledge program established by the National Institutes of
Health (2012), as well as the community-wide interactions fos-
tered by organizations such as the International Society for
Biological and Environmental Repositories, the European,
Middle Eastern & African Society for Biopreservation & Bio-
banking, and others. The inclusion of relevant expertise from the
pharmaceutical industry in handling large data sets, from their
clinical trials, for example, is likely to be critical in the devel-
opment, standardization, and adoption of big data metrics in
biobanking.
The consistent aim of any such metrics development re-
mains the more efficient characterization and management
of increasing and different amounts of data being deposited
in biobanks globally. As such, any ‘‘big data metrics’’ would
need to adhere to the customary requirements for reproduc-
ibility, transferability, scalability, and perhaps flexibility—
allowing some customization according to local needs. The
outcome is hoped to be the ability of biobanks to carry on
describing themselves well in the future and able to cope
with future demands, in terms of the information they con-
tain, and from a user perspective, the ability to locate the
relevant information alongside appropriate banked samples
for research purposes.
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